Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
ALMS
ALMS
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
ALMS News
BML Capital Management Fully Exits Alumis Stake
Feb 03 2026
Fool
Brookfield to Acquire Peakstone Realty Trust for $1.2 Billion
Feb 02 2026
Benzinga
Analysts Bullish on Century Communities, Target Price Set at $92
Jan 21 2026
Benzinga
Alumis Director Srinivas Akkaraju Purchases 588,235 Shares for ~$10 Million
Jan 17 2026
Fool
Alumis (NASDAQ:ALMS) Acquires 588,235 Shares for $10 Million
Jan 17 2026
NASDAQ.COM
Activist Investors Target Staar Surgical, Alumis, and Other Stocks
Jan 17 2026
Barron's
Russell 2000 Kicks Off 2026 Strong, Surging Over 7% Year-to-Date
Jan 15 2026
Benzinga
Alumis Inc. (ALMS) Reports 65% PASI 90 Achievement for Envudeucitinib in Psoriasis Trials
Jan 14 2026
NASDAQ.COM
Alumis Inc. Closes $345.1 Million Upsized Public Offering
Jan 09 2026
Globenewswire
Alumis Inc. Prices 17.65M Shares at $17 Each, Raising Approximately $300M
Jan 08 2026
Benzinga
Alumis Inc. Prices Upsized Public Offering of 17.65 Million Shares, Raising Approximately $300 Million
Jan 08 2026
Globenewswire
SanDisk Shares Surge 27.56% to $349.63 Amid Positive Market Sentiment
Jan 07 2026
Benzinga
Alumis Surges 95.31% on Phase 3 Psoriasis Data, Plans $175M Offering
Jan 06 2026
Fool
Alumis (ALMS) Shares Surge 95% Following Phase 3 Psoriasis Data and $175M Offering Plan
Jan 06 2026
NASDAQ.COM
Alumis Inc. Plans $175 Million Public Offering to Support R&D
Jan 06 2026
Globenewswire
Alumis Inc. Shares Surge 132% After Successful Phase 3 Trial Results
Jan 06 2026
Benzinga
Show More News
